AUCKLAND DISTRICT HEALTH BOARD
🇳🇿New Zealand
A Single CRISPR Treatment Could Replace a Lifetime of Daily Treatment in Hereditary Angioedema
A CRISPR-Cas9-based gene therapy, NTLA-2002, shows promise as a one-time treatment for hereditary angioedema (HAE), significantly reducing angioedema attacks and kallikrein levels in a phase 2 study.
© Copyright 2024. All Rights Reserved by MedPath